To determine whether AR expression level was not merely a prognostic biomarker of improved locoregional control but truly a predictive biomarker of response, we analyzed a publically available data set that included TNBC patients not treated with adjuvant radiation.13 This data set (Curtis), which included over 2000 breast cancer patients, contained details about radiation treatment and local recurrence and only those TNBC patients not treated with radiation were included in the analysis. The gene discussed is AR; the disease is breast cancer.